imatinib - Compound Summary (CID 5291) Also known as: 152459-95-5, Cgp 57148, sti-571, STI571, Imatinib Methansulfonate, STI 571, 1iep, 1xbb, Imatinib free base Molecular Formula: C 29H 31N 7O Molecular Weight: 493.60274 InChIKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.
It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. From: DrugBank |
| | |
Identification Related Records Use and Manufacturing Pharmacology Biomedical Effects and Toxicity Literature Patents Biomolecular Interactions and Pathways Biological Test Results Classification Chemical and Physical Properties |